Cargando…
Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
Antifibrotic therapy (AFT) slows disease progression in patients with idiopathic pulmonary fibrosis (IPF). The Gender-Age-Physiology (GAP) index, was developed based on data at IPF diagnosis before the introduction of AFT and has not been evaluated in the AFT context. Further, recent advances have r...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448817/ https://www.ncbi.nlm.nih.gov/pubmed/34535738 http://dx.doi.org/10.1038/s41598-021-98161-y |
_version_ | 1784569315271376896 |
---|---|
author | Suzuki, Yuzo Mori, Kazutaka Aono, Yuya Kono, Masato Hasegawa, Hirotsugu Yokomura, Koshi Naoi, Hyogo Hozumi, Hironao Karayama, Masato Furuhashi, Kazuki Enomoto, Noriyuki Fujisawa, Tomoyuki Nakamura, Yutaro Inui, Naoki Nakamura, Hidenori Suda, Takafumi |
author_facet | Suzuki, Yuzo Mori, Kazutaka Aono, Yuya Kono, Masato Hasegawa, Hirotsugu Yokomura, Koshi Naoi, Hyogo Hozumi, Hironao Karayama, Masato Furuhashi, Kazuki Enomoto, Noriyuki Fujisawa, Tomoyuki Nakamura, Yutaro Inui, Naoki Nakamura, Hidenori Suda, Takafumi |
author_sort | Suzuki, Yuzo |
collection | PubMed |
description | Antifibrotic therapy (AFT) slows disease progression in patients with idiopathic pulmonary fibrosis (IPF). The Gender-Age-Physiology (GAP) index, was developed based on data at IPF diagnosis before the introduction of AFT and has not been evaluated in the AFT context. Further, recent advances have revealed the importance of body-composition factors in prognosis of IPF treated with AFT. This multi-centre, retrospective study aimed to evaluate the GAP index and body mass index (BMI) at the time of AFT initiation for predicting prognosis in patients with IPF. This study included two patient cohorts of IPF receiving AFT, Hamamatsu cohort (n = 110) and Seirei cohort (n = 119). The distribution of GAP stages I, II, and III was 38.2%, 43.6%, and 18.2%, respectively, in Hamamatsu cohort; in Seirei cohort, it was 41.2%, 50.4%, and 8.4%, respectively. In both cohorts, the GAP index distinctly classified prognosis into three groups (log-rank test). Interestingly, a lower BMI showed prognostic value independent of the GAP index in multivariate analyses. Subsequently, combining the GAP index with BMI at AFT initiation successfully divided the patients with IPF into four distinct prognoses. Assessment of the GAP index and BMI measurement at AFT initiation are important for predicting prognosis in patients with IPF. |
format | Online Article Text |
id | pubmed-8448817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84488172021-09-21 Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis Suzuki, Yuzo Mori, Kazutaka Aono, Yuya Kono, Masato Hasegawa, Hirotsugu Yokomura, Koshi Naoi, Hyogo Hozumi, Hironao Karayama, Masato Furuhashi, Kazuki Enomoto, Noriyuki Fujisawa, Tomoyuki Nakamura, Yutaro Inui, Naoki Nakamura, Hidenori Suda, Takafumi Sci Rep Article Antifibrotic therapy (AFT) slows disease progression in patients with idiopathic pulmonary fibrosis (IPF). The Gender-Age-Physiology (GAP) index, was developed based on data at IPF diagnosis before the introduction of AFT and has not been evaluated in the AFT context. Further, recent advances have revealed the importance of body-composition factors in prognosis of IPF treated with AFT. This multi-centre, retrospective study aimed to evaluate the GAP index and body mass index (BMI) at the time of AFT initiation for predicting prognosis in patients with IPF. This study included two patient cohorts of IPF receiving AFT, Hamamatsu cohort (n = 110) and Seirei cohort (n = 119). The distribution of GAP stages I, II, and III was 38.2%, 43.6%, and 18.2%, respectively, in Hamamatsu cohort; in Seirei cohort, it was 41.2%, 50.4%, and 8.4%, respectively. In both cohorts, the GAP index distinctly classified prognosis into three groups (log-rank test). Interestingly, a lower BMI showed prognostic value independent of the GAP index in multivariate analyses. Subsequently, combining the GAP index with BMI at AFT initiation successfully divided the patients with IPF into four distinct prognoses. Assessment of the GAP index and BMI measurement at AFT initiation are important for predicting prognosis in patients with IPF. Nature Publishing Group UK 2021-09-17 /pmc/articles/PMC8448817/ /pubmed/34535738 http://dx.doi.org/10.1038/s41598-021-98161-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Suzuki, Yuzo Mori, Kazutaka Aono, Yuya Kono, Masato Hasegawa, Hirotsugu Yokomura, Koshi Naoi, Hyogo Hozumi, Hironao Karayama, Masato Furuhashi, Kazuki Enomoto, Noriyuki Fujisawa, Tomoyuki Nakamura, Yutaro Inui, Naoki Nakamura, Hidenori Suda, Takafumi Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis |
title | Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis |
title_full | Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis |
title_fullStr | Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis |
title_full_unstemmed | Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis |
title_short | Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis |
title_sort | combined assessment of the gap index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448817/ https://www.ncbi.nlm.nih.gov/pubmed/34535738 http://dx.doi.org/10.1038/s41598-021-98161-y |
work_keys_str_mv | AT suzukiyuzo combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT morikazutaka combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT aonoyuya combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT konomasato combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT hasegawahirotsugu combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT yokomurakoshi combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT naoihyogo combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT hozumihironao combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT karayamamasato combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT furuhashikazuki combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT enomotonoriyuki combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT fujisawatomoyuki combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT nakamurayutaro combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT inuinaoki combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT nakamurahidenori combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis AT sudatakafumi combinedassessmentofthegapindexandbodymassindexatantifibrotictherapyinitiationforprognosisofidiopathicpulmonaryfibrosis |